Quote | Sema4 Holdings Corp. Warrant (NASDAQ:SMFRW)
Last: | $0.024 |
---|---|
Change Percent: | -7.91% |
Open: | $0.025899 |
Close: | $0.024 |
High: | $0.026 |
Low: | $0.0181 |
Volume: | 19,048 |
Last Trade Date Time: | 01/09/2023 01:57:00 pm |
News | Sema4 Holdings Corp. Warrant (NASDAQ:SMFRW)
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
Message Board Posts | Sema4 Holdings Corp. Warrant (NASDAQ:SMFRW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Warrant Company Name:
SMFRW Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...